Atomwise's core technology, AtomNet, is a deep convolutional neural network trained on large datasets of protein-ligand interactions to predict binding affinities with high accuracy. The superplatform enables virtual screening across billions of compounds in chemical space—orders of magnitude larger than any physical compound library. The system integrates structural biology data, molecular docking, and generative chemistry to propose and prioritize novel molecules. Atomwise partners with pharmaceutical companies and academic institutions, offering its platform as a service through collaborative research agreements rather than a public API.